By Dean Seal

Bristol Myers Squibb reaffirmed long-term financial targets that call for low-to-mid single-digit annual revenue growth through 2025.

The biopharmaceutical company said in an investor presentation on Monday that it is standing behind its guidance for $8 billion to $10 billion in growth from in-line brands from 2020 to 2025. Those brands primarily include Immuno-Oncology, or IO, and the anticoagulant Eliquis, according to the presentation.

Bristol Myers said it is targeting more than 37% operating margin through 2025 and more than $10 billion in revenue from its new product portfolio in 2026.

The company is also pushing for $25 billion in non-risk adjusted sales for its new product portfolio in 2030.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

January 08, 2024 11:31 ET (16:31 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Bristol Myers Squibb Charts.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Bristol Myers Squibb Charts.